A single injection of AAV-delivered FGF21 gene therapy extended lifespan by over 20% in aged mice while preserving function across liver, kidneys, heart, skeletal muscle, and brain. The treatment improved metabolic health markers and activated adaptive programs that countered multiple aging mechanisms simultaneously, suggesting metabolic interventions may have broader relevance to systemic resilience.
Key Points
- One AAV-FGF21 injection extended median lifespan 20% in aged mice
- Treatment preserved organ function across five distinct tissue systems
- Therapy activated mitochondrial, proteostasis, and metabolic adaptive programs
Longevity Analysis
This work addresses a critical gap in longevity science: most interventions extend lifespan in mice, but few preserve function across multiple organ systems after aging is established. The breadth of systemic benefit—metabolic improvement, preserved kidney and cardiac function, maintained muscle strength and cognitive performance—suggests that sustained FGF21 expression influences interconnected biology underlying resilience and tissue maintenance rather than targeting isolated disease. The mechanism involved enhanced mitochondrial function, improved protein quality control, and suppressed inflammatory signaling across tissues, pointing to how a single intervention can coordinate adaptive responses that counteract fundamental aging processes. Whether this biology translates to humans remains the decisive question; the clinical value lies not in extra years but in preserved independence and compressed morbidity.
Original published by Longevity.Technology, by Eleanor Garth.